查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370970

治療性血漿交換市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品、技術、適應症、最終用戶、地區和競爭細分

Therapeutic Plasma Exchange Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Technology, By Indication, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球治療性血漿交易市場估值達到7.6201億美元，預計在預測期內將出現強勁成長，預計年複合成長率（CAGR）為6.75%，到2028年預計將達到11.116億美元。

主要市場促進因素：

市場概況
預測期 2024-2028
2022 年市場規模 7.6201億美元
2028 年市場規模 111160萬美元
2023-2028 年年複合成長率 6.75%
成長最快的細分市場 神經系統疾病
最大的市場 北美洲
  • 1.神經、腎臟和血液疾病的高盛行率：慢性疾病的高盛行率，包括腎病變、急性肝衰竭、格林-巴利綜合症（GBS）等，有助於整體治療性血漿交換市場的成長。治療性血漿置換的應用激增，同時進行了大量研究和臨床試驗來評估其與其他治療方法相比的療效。這些因素極大地促進了治療性血漿交換市場的成長。
  • 2.治療性血漿交換研究和開發的進展：連續流離心等高精度技術可有效分離特定的血液成分，並且正在觀察技術進步，包括下一代單採設備的開發。先進的 TPE 系統最大限度地減少人工干涉，提高程序效率，並促進此類系統在各種條件下的採用。
  • 3.擴大血漿交換治療應用的多樣性：多種神經系統疾病的治療是市場成長的重要催化劑。 TPE 被認為是治療急性發炎性脫髓鞘多發性神經根神經病變、重症肌無力 (MG) 和副腫瘤性腦病變等疾病的主要治療方法。此外，它也被用作各種其他神經系統疾病的輔助治療。這些神經系統疾病的盛行率持續上升，促進了市場的進步。
  • 4.生物製藥公司對血漿源的需求不斷成長：生物製藥公司對用於治療各種衰弱、慢性和危及生命的疾病的血漿源的需求不斷成長，這是一個重要的促進因素。血漿衍生療法在多種疾病的治療中發揮著至關重要的作用，促進了對血漿衍生產品的需求和血漿置換市場的成長。

主要市場挑戰：

  • 1.與血漿去除術相關的風險：血漿去除術涉及從人體中提取部分血液並透過靜脈注射補充液體。雖然通常被認為是安全的，但也存在相關風險，包括感染、過敏反應、低血壓、內出血、電解質失衡等。這些風險可能會限制血漿置換術的廣泛採用。
  • 2.治療性血漿交換產品的高成本：治療性血漿交換所需的專用設備（例如單採機和拋棄式組件）的成本導致了手術的高成本。品質控制流程和遵守行業標準進一步增加了成本。 TPE 產品的生產規模有限也會導致單位成本較高。

主要市場趨勢：

  • 1.持續進步：持續的技術進步提高了患者滿意度並改善了血液製品的加工。連續流離心等先進方法需要最少的血流量，這使得它們在促進血液採集方面更加先進。這些技術的發展在市場中創造了機會。
  • 2.治療性血漿程序在兒科應用的使用：治療性血漿交換治療在兒科應用的研究越來越多，用於去除各種疾病中的致病物質。這包括罕見兒科疾病和自體免疫疾病的治療，有助於市場成長。

細分洞見：

  • 1.適應症見解：由於老年族群中神經系統疾病的發生率和盛行率不斷增加以及該領域正在進行的研究，預計神經系統疾病將主導市場。
  • 2.技術見解：離心技術預計將在治療性血漿交換市場中佔據重要佔有率，這要歸功於其在供體單採術中的廣泛採用，提供成本效益和高效的血漿去除。

區域見解：

北美在全球治療性血漿交換市場中佔據主導地位，自體免疫疾病的高盛行率、完善的醫院基礎設施以及生物技術企業的強大影響力等因素促進了其成長。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球治療性血漿交換市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品（消耗品、設備）
    • 依技術分類（離心、膜分離）
    • 依適應症（神經系統疾病、血液系統疾病、腎臟疾病、代謝性疾病、其他）
    • 按最終使用者（採血中心和血液成分提供者、醫院和診所、輸血中心、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美治療性血漿交換市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按指示
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲治療性血漿交換市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按指示
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區治療性血漿交換市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按指示
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲治療性血漿交換市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按指示
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲治療性血漿交換市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按指示
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非治療性血漿交換
    • 沙烏地阿拉伯治療性血漿交換
    • 阿拉伯聯合大公國治療性血漿交換

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球治療性血漿交換市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Asahi Kasei Corporation
    • Baxter International Inc
    • B. Braun Melsungen AG
    • Cerus Corporation
    • Fresenius Kabi AG
    • Haemonetics Corporation
    • Hemacare Corporation
    • IncMedica SpA
    • Kawasumi Laboratories
    • Terumo Corporation

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 4598

The Global Therapeutic Plasma Exchange Market reached a valuation of USD 762.01 Million in 2022 and is expected to experience robust growth during the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 6.75% and expected to reach USD 1111.60 Million through 2028.

Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an advanced medical procedure used to separate pathogenic substances from patients' blood and replace them with replacement fluids, such as albumin solution or fresh frozen plasma. These substances include infective autoantibodies, immune complexes, cryoglobulins, and cholesterol-containing lipoproteins. TPE is widely employed in the treatment of various autoimmune conditions, renal disorders, hematological disorders, and more, contributing significantly to market expansion. It also offers the significant benefit of reducing plasma viscosity and is utilized in the management of chronic diseases as a first-line or second-line therapy or as a supportive treatment. During plasma exchange, a substantial portion of plasma containing toxins and other abnormal matter is extracted from the other blood components and replaced with replacement fluid, such as fresh frozen plasma (FFP) or albumin.

Key Market Drivers:

Market Overview
Forecast Period2024-2028
Market Size 2022USD 762.01 Million
Market Size 2028USD 1111.60 Million
CAGR 2023-20286.75%
Fastest Growing SegmentNeurological Disorders
Largest MarketNorth America
  • 1. High Prevalence of Neurological, Renal, and Hematological Disorders: The high prevalence of chronic diseases, including nephrological disorders, acute liver failure, Guillain-Barre Syndrome (GBS), and others, contributes to the growth of the overall therapeutic plasma exchange market. There has been a surge in the application of therapeutic plasma exchange, accompanied by intensive research and clinical trials to assess its efficacy compared to other treatments. These factors significantly bolster the growth of the therapeutic plasma exchange market.
  • 2. Advances in Therapeutic Plasma Exchange Research and Development: High-precision technologies like continuous-flow centrifugation effectively separate specific blood components, and technological advancements, including the development of next-generation apheresis devices, are being observed. Advanced TPE systems minimize manual intervention, enhance procedure efficiency, and promote the adoption of such systems for a wide range of conditions.
  • 3. Expanding Variety of Therapeutic Plasma Exchange Applications: The treatment of a wide array of neurological disorders serves as a significant catalyst for market growth. TPE is considered the primary treatment for conditions such as acute inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis (MG), and paraneoplastic encephalopathies. Additionally, it is employed as a secondary treatment for various other neurological conditions. The prevalence of these neurological disorders continues to rise, contributing to market progress.
  • 4. Increasing Demand for Source Plasma from Biopharmaceutical Companies: The growing demand for source plasma from biopharmaceutical companies for the treatment of various debilitating, chronic, and life-threatening disorders is a significant driver. Plasma-derived therapies play a crucial role in the treatment of a broad spectrum of diseases, contributing to the demand for plasma-derived products and the growth of the plasmapheresis market.

Key Market Challenges:

  • 1. Risk Associated with Plasmapheresis Procedures: Plasmapheresis procedures involve extracting a portion of blood from the human body and administering replacement fluids intravenously. While generally considered safe, there are associated risks, including infection, allergic reactions, hypotension, internal bleeding, electrolyte imbalance, and others. These risks may limit the widespread adoption of plasmapheresis.
  • 2. High Cost of Therapeutic Plasma Exchange Products: The cost of specialized equipment required for therapeutic plasma exchange, such as apheresis machines and disposable components, contributes to the high cost of the procedure. Quality control processes and compliance with industry standards further add to the cost. The limited scale of production for TPE products can also lead to higher per-unit costs.

Key Market Trends:

  • 1. Continuous Advancement: Ongoing technological advancements enhance patient satisfaction and improve the processing of blood-derived goods. Advanced methods like continuous-flow centrifugation require minimal blood flow, making them more advanced for facilitating blood collection. These technological developments create opportunities within the market.
  • 2. Use of Therapeutic Plasma Procedure in Pediatric Applications: Therapeutic plasma exchange treatments are increasingly studied for pediatric applications in the removal of pathogenic materials in various diseases. This includes the treatment of rare pediatric disorders and autoimmune diseases, contributing to market growth.

Segmental Insights:

  • 1. Indication Insights: Neurological disorders are expected to dominate the market, driven by the increasing incidence and prevalence of these diseases in the geriatric population and ongoing research in this field.
  • 2. Technology Insights: Centrifugation technology is projected to hold a significant share in the Therapeutic Plasma Exchange market, thanks to its widespread adoption in donor apheresis, offering cost-effectiveness and efficient plasma removal.

Regional Insights:

North America dominates the global therapeutic plasma exchange market, with factors such as a high prevalence of autoimmune diseases, a well-established hospital infrastructure, and a strong presence of biotech enterprises contributing to its growth.

Key Market Players

  • Asahi Kasei Corporation
  • Baxter International Inc
  • B. Braun Melsungen AG
  • Cerus Corporation
  • Fresenius Kabi AG
  • Haemonetics Corporation
  • Hemacare Corporation
  • IncMedica S.p.A.
  • Kawasumi Laboratories
  • Terumo Corporation

Report Scope:

In this report, the Global Therapeutic Plasma Exchange Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Therapeutic Plasma Exchange Market, By Product:

  • Consumables
  • Devices

Therapeutic Plasma Exchange Market, By Technology:

  • Centrifugation
  • Membrane Separation

Therapeutic Plasma Exchange Market, By Indication:

  • Neurological Disorders
  • Haematology Disorders
  • Renal Disorders
  • Metabolic Disorders
  • Others

Therapeutic Plasma Exchange Market, By End User:

  • Blood Collection Centres & Blood Component Providers
  • Hospitals & Clinics
  • Blood Transfusion Centres
  • Others

Therapeutic Plasma Exchange Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.

Available Customizations:

  • Global Therapeutic Plasma Exchange market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutic Plasma Exchange Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Consumables, Devices)
    • 5.2.2. By Technology (Centrifugation, Membrane Separation)
    • 5.2.3. By Indication (Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, Others)
    • 5.2.4. By End User (Blood Collection Centers & Blood Component Providers, Hospitals & Clinics, Blood Transfusion Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Therapeutic Plasma Exchange Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Indication
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Therapeutic Plasma Exchange Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Indication
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Therapeutic Plasma Exchange Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Indication
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Therapeutic Plasma Exchange Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Indication
        • 6.3.3.2.4. By End User

7. Europe Therapeutic Plasma Exchange Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Indication
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Therapeutic Plasma Exchange Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Indication
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Therapeutic Plasma Exchange Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Indication
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Therapeutic Plasma Exchange Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Indication
        • 7.3.3.2.4. By End User
    • 7.3.4. France Therapeutic Plasma Exchange Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Indication
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Therapeutic Plasma Exchange Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Indication
        • 7.3.5.2.4. By End User

8. Asia-Pacific Therapeutic Plasma Exchange Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Indication
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Therapeutic Plasma Exchange Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Indication
        • 8.3.1.2.4. By End User
    • 8.3.2. India Therapeutic Plasma Exchange Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Indication
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Therapeutic Plasma Exchange Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Indication
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Therapeutic Plasma Exchange Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Indication
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Therapeutic Plasma Exchange Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Indication
        • 8.3.5.2.4. By End User

9. South America Therapeutic Plasma Exchange Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Indication
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Therapeutic Plasma Exchange Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Indication
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Therapeutic Plasma Exchange Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Indication
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Therapeutic Plasma Exchange Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Indication
        • 9.3.3.2.4. By End User

10. Middle East and Africa Therapeutic Plasma Exchange Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
    • 10.2.3. By Indication
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Therapeutic Plasma Exchange Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Indication
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Therapeutic Plasma Exchange Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Indication
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Therapeutic Plasma Exchange Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Indication
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Therapeutic Plasma Exchange Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Asahi Kasei Corporation
    • 15.5.2. Baxter International Inc
    • 15.5.3. B. Braun Melsungen AG
    • 15.5.4. Cerus Corporation
    • 15.5.5. Fresenius Kabi AG
    • 15.5.6. Haemonetics Corporation
    • 15.5.7. Hemacare Corporation
    • 15.5.8. IncMedica S.p.A.
    • 15.5.9. Kawasumi Laboratories
    • 15.5.10. Terumo Corporation

16. Strategic Recommendations

17. About Us & Disclaimer